Logo image of ASMB

ASSEMBLY BIOSCIENCES INC (ASMB) Stock Fundamental Analysis

NASDAQ:ASMB - Nasdaq - US0453962070 - Common Stock - Currency: USD

12.35  -0.4 (-3.14%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ASMB. ASMB was compared to 572 industry peers in the Biotechnology industry. While ASMB seems to be doing ok healthwise, there are quite some concerns on its profitability. ASMB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ASMB has reported negative net income.
In the past year ASMB had a positive cash flow from operations.
In the past 5 years ASMB always reported negative net income.
In the past 5 years ASMB reported 4 times negative operating cash flow.
ASMB Yearly Net Income VS EBIT VS OCF VS FCFASMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -40.70%, ASMB is in line with its industry, outperforming 55.06% of the companies in the same industry.
ASMB has a Return On Equity of -156.92%. This is in the lower half of the industry: ASMB underperforms 66.07% of its industry peers.
Industry RankSector Rank
ROA -40.7%
ROE -156.92%
ROIC N/A
ROA(3y)-68.06%
ROA(5y)-50.97%
ROE(3y)-112.82%
ROE(5y)-80.01%
ROIC(3y)N/A
ROIC(5y)N/A
ASMB Yearly ROA, ROE, ROICASMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ASMB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASMB Yearly Profit, Operating, Gross MarginsASMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASMB has more shares outstanding
The number of shares outstanding for ASMB has been increased compared to 5 years ago.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASMB Yearly Shares OutstandingASMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
ASMB Yearly Total Debt VS Total AssetsASMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -11.32, we must say that ASMB is in the distress zone and has some risk of bankruptcy.
ASMB's Altman-Z score of -11.32 is on the low side compared to the rest of the industry. ASMB is outperformed by 76.20% of its industry peers.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -11.32
ROIC/WACCN/A
WACC9.44%
ASMB Yearly LT Debt VS Equity VS FCFASMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 2.36 indicates that ASMB has no problem at all paying its short term obligations.
With a Current ratio value of 2.36, ASMB is not doing good in the industry: 72.82% of the companies in the same industry are doing better.
ASMB has a Quick Ratio of 2.36. This indicates that ASMB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.36, ASMB is doing worse than 71.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2.36
ASMB Yearly Current Assets VS Current LiabilitesASMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

ASMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.16%, which is quite impressive.
ASMB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.51% yearly.
EPS 1Y (TTM)57.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.4%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.09%
Revenue growth 5Y-13.51%
Sales Q2Q%N/A

3.2 Future

ASMB is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.7%
EPS Next 2Y19.56%
EPS Next 3Y9.64%
EPS Next 5Y-2.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ASMB Yearly Revenue VS EstimatesASMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
ASMB Yearly EPS VS EstimatesASMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ASMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASMB Price Earnings VS Forward Price EarningsASMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ASMB is valued cheaper than 99.47% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.44
EV/EBITDA N/A
ASMB Per share dataASMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.56%
EPS Next 3Y9.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASMB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (2/21/2025, 8:01:57 PM)

12.35

-0.4 (-3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners50.36%
Inst Owner Change-94.86%
Ins Owners12.08%
Ins Owner Change10.84%
Market Cap78.55M
Analysts82.22
Price Target36.21 (193.2%)
Short Float %0.41%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.83%
Min EPS beat(2)12.95%
Max EPS beat(2)26.71%
EPS beat(4)4
Avg EPS beat(4)29.02%
Min EPS beat(4)12.95%
Max EPS beat(4)49.61%
EPS beat(8)4
Avg EPS beat(8)11.3%
EPS beat(12)6
Avg EPS beat(12)8.83%
EPS beat(16)9
Avg EPS beat(16)10.1%
Revenue beat(2)1
Avg Revenue beat(2)9.01%
Min Revenue beat(2)-22.37%
Max Revenue beat(2)40.39%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)3.45%
Revenue NQ rev (1m)-33.34%
Revenue NQ rev (3m)-33.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.77
P/FCF 3.44
P/OCF 3.42
P/B 3.02
P/tB 3.02
EV/EBITDA N/A
EPS(TTM)-7.3
EYN/A
EPS(NY)-7.8
Fwd EYN/A
FCF(TTM)3.59
FCFY29.08%
OCF(TTM)3.61
OCFY29.2%
SpS4.45
BVpS4.09
TBVpS4.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.7%
ROE -156.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 80.63%
ROA(3y)-68.06%
ROA(5y)-50.97%
ROE(3y)-112.82%
ROE(5y)-80.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 54.7%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.36
Quick Ratio 2.36
Altman-Z -11.32
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)247.18%
Cap/Depr(5y)275.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.4%
EPS Next Y43.7%
EPS Next 2Y19.56%
EPS Next 3Y9.64%
EPS Next 5Y-2.28%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.09%
Revenue growth 5Y-13.51%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y126.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y127.12%
OCF growth 3YN/A
OCF growth 5YN/A